The groundbreaking success of Sildenafil undeniably transformed the drug landscape, but investing in companies primarily reliant on off-patent versions presents a uncertain picture. Although early profits were substantial, the end of patents and the emergence of cheaper alternatives have diminished sales. Thus, a thorough analysis of ongoing revenu